Welcome to our dedicated page for Verona Pharma SEC filings (Ticker: VRNA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Verona Pharma plc filings document the regulatory record of a U.K. respiratory biopharmaceutical issuer whose ordinary shares were represented by American Depositary Shares on Nasdaq. The filings describe the ADS security structure, with each ADS representing eight ordinary shares, material-event reports, governance matters, shareholder voting items, capital-structure disclosures, and operating and financial results.
The company’s later SEC record also documents its completed acquisition by Merck and the resulting corporate-status change. A Form 25 filed by Nasdaq records the removal of Verona Pharma’s American Depositary Shares from listing and registration, while related Form 8-K reports address material agreements, governance and compensation matters, clinical or regulatory disclosures, and transaction-related events.
Verona Pharma plc (VRNA) – Form 4 insider filing
Chief Financial Officer Mark W. Hahn reported two equity transactions on 7 Jul 2025-8 Jul 2025.
- Equity award & conversion: 675,048 performance-based Restricted Share Units (RSUs) were granted after the Board confirmed that Q2 2025 performance metrics were met. On the same day 229,512 Ordinary Shares (≈28,689 ADSs) were issued on RSU conversion at a cost basis of $0.
- Tax withholding: 90,320 Ordinary Shares (≈11,290 ADSs) were automatically withheld at an effective price of $11.4413 to satisfy tax obligations; no open-market sale occurred.
- Post-transaction ownership: Hahn now holds 12,418,184 Ordinary Shares (≈1.55 million ADSs), all in direct ownership.
Because the RSUs vested only after Q2 targets were achieved, the filing signals that internal performance hurdles were met, a modestly positive data-point for investors. The net share movement (≈+139,000 Ordinary Shares) increases the CFO’s equity exposure, aligning his incentives with shareholders.
Verona Pharma plc (VRNA) – Form 4 insider transaction
General Counsel Andrew Fisher reported a series of equity transactions on 7-8 July 2025:
- 253,120 Ordinary Shares underlying new performance-based Restricted Share Units (RSUs) were granted on 7 July 2025 (Code A). These RSUs have no expiry; 34 % vested immediately with the remainder vesting quarterly over two years, subject to continued service.
- 86,064 Ordinary Shares were acquired for $0 upon RSU settlement (Code M).
- 39,464 Ordinary Shares were withheld (Code F) at $11.4413 per share to satisfy tax obligations related to the vesting event.
After these transactions Fisher directly owns 406,599 Ordinary Shares (≈50,825 ADSs) and holds 167,056 unvested RSUs (≈20,882 ADSs). Each ADS represents eight Ordinary Shares.
No open-market purchases or discretionary sales occurred; share withholding is an automatic tax-settlement mechanism. The filing indicates that Q2-2025 performance goals were met, triggering the RSU award and partial vesting.
Merck Sharp & Dohme LLC has signed a Transaction Agreement to acquire Verona Pharma plc (VRNA) via a U.K. court-sanctioned Scheme of Arrangement.
Merck’s wholly owned vehicle, Vol Holdings LLC, will pay $13.375 in cash for each ordinary share, equivalent to $107 in cash for every ADS (8 ordinary shares). All unvested equity awards will fully vest and be cashed out at closing if their exercise price is below the offer value; underwater options will be cancelled.
The Verona Board unanimously backs the deal and will recommend shareholder approval in a forthcoming proxy statement. Directors and key executives have executed a Voting Agreement obligating them to vote in favor of the transaction.
The agreement includes: (i) customary non-solicitation covenants, (ii) a right to consider a bona fide superior proposal, and (iii) a $100 million termination fee payable to Merck under specified circumstances. Either party may terminate if the deal is not completed by 8 January 2026, extendable twice (three months each) for outstanding regulatory approvals.
Closing remains subject to Verona shareholder approval, U.K. High Court sanction, and regulatory clearances. A joint press release announcing the agreement was issued on 9 July 2025.